Association between HLA-DPB1 supertypes (carrier/noncarrier) and risk of childhood ALL overall and by subtype, NCCLS, 1995-2008
| Supertype† . | % carriers of DPB1 supertype . | OR (95% CI)* . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total ALL . | cALL . | Hyperdiploid . | TEL-AML1 . | Normal‡ . | Controls . | Total ALL . | cALL . | Hyperdiploid . | TEL-AML1 . | Normal karyotype‡ . | |
| DP2 (GEG) | 24.8 | 24.1 | 22.1 | 24.7 | 22.9 | 24.5 | 1.03 (0.80-1.31) | 0.97 (0.70-1.34) | 0.88 (0.59-1.31) | 0.99 (0.59-1.66) | 0.93 (0.52-1.66) |
| DP4 (GKG) | 79.2 | 79.4 | 77.9 | 76.4 | 74.3 | 80.9 | 0.88 (0.68-1.15) | 0.91 (0.64-1.29) | 0.82 (0.55-1.23) | 0.78 (0.46-1.32) | 0.67 (0.38-1.18) |
| DP6 (LED) | 14.2 | 14.8 | 15.1 | 15.7 | 22.9 | 15.0 | 0.94 (0.70-1.27) | 1.17 (0.79-1.74) | 1.03 (0.65-1.64) | 1.13 (0.61-2.08) | 1.68 (0.93-3.04) |
| DP3 (LKD) | 19.5 | 17.9 | 19.2 | 20.2 | 21.4 | 20.2 | 0.96 (0.73-1.25) | 0.80 (0.56-1.15) | 0.94 (0.62-1.42) | 0.92 (0.53-1.60) | 1.11 (0.61-2.01) |
| DP8 (GED) | 3.4 | 3.1 | 2.9 | 2.3 | 2.9 | 2.2 | 1.52 (0.80-2.88) | 1.09 (0.47-2.51) | 1.21 (0.44-3.33) | 0.90 (0.20-3.99) | 1.29 (0.29-5.66) |
| DP1 (GKD) | 16.2 | 16.2 | 20.9 | 19.1 | 14.3 | 12.7 | 1.33 (0.99-1.79) | 1.33 (0.90-1.96) | 1.83 (1.20-2.78) | 1.64 (0.92-2.91) | 1.14 (0.26-2.29) |
| n subjects | 585 | 291 | 172 | 89 | 70 | 848 | |||||
| Supertype† . | % carriers of DPB1 supertype . | OR (95% CI)* . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total ALL . | cALL . | Hyperdiploid . | TEL-AML1 . | Normal‡ . | Controls . | Total ALL . | cALL . | Hyperdiploid . | TEL-AML1 . | Normal karyotype‡ . | |
| DP2 (GEG) | 24.8 | 24.1 | 22.1 | 24.7 | 22.9 | 24.5 | 1.03 (0.80-1.31) | 0.97 (0.70-1.34) | 0.88 (0.59-1.31) | 0.99 (0.59-1.66) | 0.93 (0.52-1.66) |
| DP4 (GKG) | 79.2 | 79.4 | 77.9 | 76.4 | 74.3 | 80.9 | 0.88 (0.68-1.15) | 0.91 (0.64-1.29) | 0.82 (0.55-1.23) | 0.78 (0.46-1.32) | 0.67 (0.38-1.18) |
| DP6 (LED) | 14.2 | 14.8 | 15.1 | 15.7 | 22.9 | 15.0 | 0.94 (0.70-1.27) | 1.17 (0.79-1.74) | 1.03 (0.65-1.64) | 1.13 (0.61-2.08) | 1.68 (0.93-3.04) |
| DP3 (LKD) | 19.5 | 17.9 | 19.2 | 20.2 | 21.4 | 20.2 | 0.96 (0.73-1.25) | 0.80 (0.56-1.15) | 0.94 (0.62-1.42) | 0.92 (0.53-1.60) | 1.11 (0.61-2.01) |
| DP8 (GED) | 3.4 | 3.1 | 2.9 | 2.3 | 2.9 | 2.2 | 1.52 (0.80-2.88) | 1.09 (0.47-2.51) | 1.21 (0.44-3.33) | 0.90 (0.20-3.99) | 1.29 (0.29-5.66) |
| DP1 (GKD) | 16.2 | 16.2 | 20.9 | 19.1 | 14.3 | 12.7 | 1.33 (0.99-1.79) | 1.33 (0.90-1.96) | 1.83 (1.20-2.78) | 1.64 (0.92-2.91) | 1.14 (0.26-2.29) |
| n subjects | 585 | 291 | 172 | 89 | 70 | 848 | |||||
cALL indicates common ALL; E, glutamic acid; G, glycine; L, leucine; D, aspartic acid; and K, lysine.
ORs and 95% CIs were calculated using logistic regression adjusting for child's age, sex, and race/ethnicity. Importance of adjustment by other supertypes was evaluated based on the criteria of a > 10% change in OR of the supertype in question. This adjustment did not remarkably influence the risk estimate for all supertypes.
Supertypes based on peptide-binding pocket residue sequences: pocket 6, position 11; pocket 4, position 69; and pocket 1, position 84.
Normal cytogenetics results with a minimum of 20 metaphases counted.